News and Comments


  Wednesday, June 20, 2012

The FDA Oncologic Drugs Advisory Committee (ODAC) voted 11-0 with 1 abstention in favor of approval of Onyx (ONXX) multiple myeloma drug Kyprolis™(carfilzomib). The recommendation is for patients with relapsed and refractory multiple myeloma who have received at least two prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent (IMiD), the benefit-risk assessment is favorable for the use of Kyprolis™.  More...


  Wednesday, June 20, 2012

When on February 24, 2012, we wrote that the Pharmacyclics (PCYC) story is one of only a few in which the power of the firm’s product pipeline overshadows the stock market’s technical influence, we were not hallucinating, as some have claimed. With this firm’s drug ibrutinib (PCI-32765) demonstrating safety and efficacy in various blood cancers, negative unsubstantiated speculations failed to persuade investors to cease investing in PCYC. Trial results have confirmed the superiority of ibrutinib in treating B-cell cancers, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM).  More...

ImmunoGen has good news and any “BUT” is not relevant at this time.

  Monday, June 04, 2012

The media seems to have woken up from its unconsciousness, overlooking good news in favor of perpetrating negative energy that weighs heavily on people’s psyche. When undeniable cheerful realities emerge, the media can no more ignore it. That’s what we see happening at least in the biotechnology sector these days. Years of overlooking breakthrough approaches that demonstrate promise of improving the prognosis of cancers known to resist conventional treatments have ended and the negative media could not hide its admiration of what it is actually witnessing. Some would find a space to put a “BUT” after praising the drug, but investors have developed expertise in interpreting the but that is put in the wrong place. More...

Recent Postings



Editas (EDIT) Exelixis (EXEL) Auspex (ASPX) SYNTA (SNTA) Ariad (ARIA) Zerenex Aimmune Therapeutics (AIMT) Inovio (INO) Anadys (ANDS) NEKTAR (NKTR)) Prolor Biotech (PBTH) Prosensa (RNA) Amgen (AMGN) ImmunoGen (IMGN) VANDA (VNDA) Human Genome Sciences (HGSI) Human Longevity (HLI) ADVENTRIX (ANX) Herceptin ARGOS (ARGS) Onyx (ONXX) Intrexon (XON) Ridaforolimus CRISPR Therapeutics (CRSP) Elan (ELN) Seattle Genetics (SGEN) Multiple Myeloma RenenxBio (RGNX) SUNESIS PHARMACEUTICALS (SNSS) Incyte (INCY) Ocular Therapeutix (OCUL) C4 Therapeutics GlaxoSmithKline (GSK) Vitae Pharmaceuticals (VTAE) Sanofi-Aventis (SAN) GUARDIAN HEALTH Cytokinetics (CYTK) OSI (OSIP) Velcade (bortezomib) TOKAI (TKAOI) Illumina (ILMN) AstraZeneca (AZN) Sanofi (SNY) IDERA (IDRA) INNOVIVA (INVA) NOVOCURE (NVCR) ARCA (ABIO) Ionis (IONS) Dendreon (DNDN) Vertex (VRTX) Jazz Pharmaceuticals (JAZZ) Pluristem (PSTI) galapagos (GLPG) Sanofi (SNA) Adaptimmune (ADAP) Merck (MRK) ISIS (ISIS) SERES THERAPEUTICS (MCRB) Regeneron (REGN) REGULUS (RGLS) Global Cell Therapeutics (GBT) Sangamo (SGMO) Rapamune Intermune (ITMN) Sequenom (SQNM) Gilead (GILD) AERIE PHARMACEUTICALS Sarepta (SRPT) Agenus (AGEN) Valeant Pharmaceuticals International (VRX) Micromet (MITI) Bristol-Myers Squibb (BMY) Telaprevir Spike Therapeutics (ONCE) Roche (RHHBY) Idenix (IDIX) Bellicum (BLCM) Theravance Bio Pharma (TBPH) Agenus (AGEN Biocryst (BCRX) Trastuzumab-DM1 PTC Therapeutics (PTCT) Endometrial Cancer ACADIA (ACAD) Abbott Laboratories (ABT) ZALTRAP™ Biogen Idec (BIIB) Intercept (ICPT) NANTKWEST (NK) Advaxis (ADXS) Ziofpharm (ZIOP) JUNO (JUNO) AGOS (ARGS) Revlimid (lenolidamide) Array Pharmaceuticals (ARRY) Benlysta (belimumab) KERYX (KERX) HALOZYME (HALO) Dynavax (DVAX) Mirati Therapeutics (MRTX) Xoma (XOMA) MODERNA Anacor (ANAC) ABBVIE (ABBV) KITE (KITE) Theravance (THRX) Roche (ROCHE) Tysabri Alnylam (ALNY) CEMPRA (CEMP) Galena (GALE) Genentech BIOMARIN (BMRN) CompuGen (CGEN) Alder Biopharmaceuticals (ALDR)